Capricor Therapeutics Advances with Strategic Expansions
Company Announcements

Capricor Therapeutics Advances with Strategic Expansions

Capricor Therapeutics, Inc. ( (CAPR) ) has released its Q3 earnings. Here is a breakdown of the information Capricor Therapeutics, Inc. presented to its investors.

Capricor Therapeutics, Inc., a biotechnology company, specializes in developing innovative cell and exosome-based therapies for rare diseases, with a focus on cardiac and dystrophinopathies. The company recently released its third-quarter 2024 financial results and provided a corporate update, highlighting significant advancements and strategic developments.

Capricor announced the commencement of a biologics license application for deramiocel, a therapy for DMD-cardiomyopathy, with the full submission expected by the end of 2024. The company also reported positive data from its HOPE-2 OLE trial and expanded its StealthX exosome platform. A partnership with Nippon Shinyaku was signed for European commercialization, potentially bringing $1.5 billion in milestones.

Financially, Capricor’s cash position strengthened significantly, reaching $85 million due to a public offering. However, the company reported a net loss of $12.6 million for the quarter, with expenses rising to $15.3 million. Despite a decline in quarterly revenue to $2.3 million, Capricor remains optimistic about its cash runway supporting operations into 2027.

Looking ahead, Capricor continues to focus on expanding manufacturing capabilities and exploring non-dilutive funding options, signaling an optimistic outlook as it prepares for potential product commercialization pending regulatory approvals.

Related Articles
TheFlyCapricor Therapeutics reports Q3 EPS (38c), consensus (36c)
TheFlyCapricor Therapeutics options imply 8.1% move in share price post-earnings
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App